Controversies with Kalydeco: Newspaper coverage in Canada and the United States of the cystic fibrosis “wonder drug”  by Rachul, Christen et al.
www.else
Journal of Cystic Fibrosis 15 (2016) 624–629Original Article⁎ Corresponding author. Tel.:+1 780 4928358.
E-mail addresses: christenrachul@cmail.carleton.ca (C. Rachul),
maeghan@ualberta.ca (M. Toews), caulﬁeld@ualberta.ca (T. Caulﬁeld).
http://dx.doi.org/10.1016/j.jcf.2016.03.006
1569-1993/© 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under t
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).vier.com/locate/jcfControversies with Kalydeco: Newspaper coverage
in Canada and the United States of the cystic ﬁbrosis “wonder drug”
Christen Rachul a, Maeghan Toews b, Timothy Caulﬁeld c,⁎
a School of Linguistics and Language Studies, Carleton University, Paterson Hall 236, 1125 Colonel By Drive, Ottawa, ON K1S 5B6, Canada
b Health Law Institute, Faculty of Law, University of Alberta, Edmonton, AB T6G 0H5, Canada
c Health Law Institute, Faculty of Law and School of Public Health, University of Alberta, Edmonton, AB T6G 0H5, Canada
Received 21 January 2016; revised 15 March 2016; accepted 24 March 2016
Available online 14 April 2016Abstract
Background: The cystic ﬁbrosis drug, Kalydeco, has attracted attention both for its effectiveness in particular CF patients and its substantial price
tag. An analysis of newspaper portrayals of Kalydeco provides an opportunity to examine how policy issues associated with rare diseases and
orphan drugs are being represented in the popular press.
Methods: We conducted a content analysis of 203 newspaper articles in Canada and the U.S. that mention Kalydeco. Articles were analyzed for
their main frame, discussion of Kalydeco, including issues of drug development, patient access, and reimbursement, and overall tone.
Results: In Canadian newspaper coverage, 77.4% of articles were framed as human interest stories featuring individual patients seeking public
funding for Kalydeco, yet only 7.5% mentioned any budgetary limitations in doing so. In contrast, U.S. newspaper coverage was framed as a
ﬁnancial/economic story in 43.1% of articles and a medical/scientiﬁc story in 27.8%.
Conclusions: Newspaper coverage varied signiﬁcantly between Canada, where Kalydeco is predominantly a story about increasing patient access
through full government funding, and the U.S., where Kalydeco is largely a ﬁnancial story about the economic impact of Kalydeco. The difference
in coverage may be due to differences in public funding between the healthcare systems of these two countries.
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Kalydeco; Orphan drug; Venture philanthropy; Drug reimbursement; Patient access1. Introduction
The 2012 FDA approval of the cystic fibrosis (CF) drug,
Kalydeco® (ivacaftor), marked a significant advancement in CF
treatment. Kalydeco was the first drug to treat the underlying
cause of the disease and is very effective for approximately 4–5%
of CF patients with certain genetic variants [1,2]. However, the
process through which Kalydeco was developed and the price of
the drug set by its developer, Vertex Pharmaceuticals, have
caused some concern for policymakers.Kalydeco is one of the most expensive drugs on the market,
priced at approximately $300,000 per patient per year [1].
Although orphan drugs (drugs used to treat patients with rare
diseases) are often priced relatively high, in part, because of
high research and development costs and low patient volumes,
the price of Kalydeco has been criticized by members of the
medical community as “unconscionable” and in excess of what
is necessary to recoup R&D costs [1,3]. In particular, the price
of Kalydeco represents “a 10-fold increase in a typical patient's
total drug costs” [3]. The high price of Kalydeco is also
controversial because it was developed using charitable funds
from the Cystic Fibrosis Foundation (CFF) and relied on the
results of basic research funded with public dollars [4]. The
CFF invested an initial $75 million in the drug's development
with a subsequent $75 million investment in Vertex for furtherhe CC BY-NC-ND
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Kalydeco for $3.3 billion [6,7].
Kalydeco is representative of many of the policy issues
associated more broadly with rare diseases and orphan drugs. The
price and clinical effectiveness of orphan drugs is a significant
issue for policymakers and those responsible for making
reimbursement decisions [8] with significant implications for
patient access [8,9]. In the U.S., Kalydecowas accepted relatively
quickly by Medicaid programs and private insurers [7,10,11],
while coverage elsewhere was more challenging [11,12]. The
decision to fund Kalydeco in England appears to have impacted
the decisions of other UK jurisdictions, such as Scotland, which
decided to fund the drug just days after the Scottish Medicines
Consortium advised against it [11,12]. In Australia and Canada,
there were protracted negotiations with Vertex over the price of
the drug, with patient groups lobbying politicians to provide
funding [11–14].
Given the attention Kalydeco has received by policymakers,
patient groups and the media, as well as the novel nature of the
CFF's involvement in Kalydeco's development, analyzing
newspaper coverage of this drug provides a unique opportunity
to examine how policy issues and controversies associated with
orphan drugs are being portrayed. Specifically, news media
coverage can play a role in the healthcare system [15] and
complicate debates about public health policy issues [16]. News
media coverage may also impact how policy debates associated
with funding decisions are framed, play out, and are ultimately
resolved [17,18]. In addition, the media can reflect and shape
public opinion [16,19] and affect public perceptions of the
seriousness of diseases and health issues [20]. Since popular
media is a primary source of health and science information [21],
examining news media portrayals of Kalydeco may provide
insight into how the debate surrounding reimbursement and
patient access has been framed and what information the public
has been provided about the benefits, costs and controversies of
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Fig. 1. Framing of news articles by country.2. Methods
Our study examines media coverage of Kalydeco in Canada
and the U.S., which share many social, cultural, and economic
similarities, but whose healthcare systems have different funding
and delivery structures [22]. Using the Factiva database, we
compiled a data set of English-language news articles published
in national, regional, and local newspapers. Due to the limitations
of the Factiva database, our data set is not comprehensive of all
media coverage and only considers text without accompanying
images; however, the data set provides a representative sample of
media coverage and text alone can still provide insight into how
the media has framed the story of Kalydeco. We searched the
Factiva database using the search term “Kalydeco.”Articles up to
and including those published on January 31st, 2015 were
collected from 51 different newspapers, yielding 370 articles,
with the earliest article appearing on October 11th, 2011. Stock
reports were eliminated from the data set, resulting in a final data
set of 290 articles. Altogether there were 203 original articles, 87of which were reprinted in separate newspapers and included in
the final data set.
Analysis of news articles was conducted in two stages. First,
a random sample of 20 articles (roughly 10% of original
articles) was selected from the data set for exploratory, thematic
coding by three coders [23]. Results from the qualitative coding
were then compared to identify common themes. Second, a
coding framework was developed based on the themes elicited
from the qualitative analysis. This framework was designed to
elicit information from each article about the main frame of the
story, description and details about Kalydeco, discussions
about funding the drug's development and patients' access to
the drug, and the overall tone of the article. Two coders applied
the coding framework to the data set of original articles. Final
results were calculated including the 87 reprinted articles. A
third coder coded a random sample of 40 articles to measure
inter-coder reliability. Cohen's Kappa was used to calculate
inter-coder reliability. Results ranged from k = 0.631 to 1.000
indicating good to very good agreement.
3. Results
3.1. Framing of news stories
Four major story frames were identified during the
qualitative coding stage of the study: 1) economic/financial,
including stories about the economic implications for patients,
government, and Vertex; 2) human interest, including stories
featuring specific patients' experiences regarding Kalydeco; 3)
medical/scientific, including stories discussing the medical or
scientific breakthroughs associated with Kalydeco; and 4)
policy/governance, including stories discussing policy and
legislative issues associated with rare diseases and orphan
drugs. The results highlight a stark contrast between Canadian
and U.S. news coverage (Fig. 1).
3.2. Descriptions of CF and Kalydeco
Articles were coded for whether CF was described as a rare
disease. Only 10 Canadian articles (6.8%, 10/146) and 29 U.S.
Table 1
Top descriptors for Kalydeco in Canada and U.S.
Canada U.S.
Life-saving (55 articles) Breakthrough (7 articles)
Wonder drug (36 articles) Wonder drug (3 articles)
Expensive (14 articles) Closest thing to a cure for
CF (3 articles)
Breakthrough (5 articles)
Closest thing to a cure for
CF (3 articles)
Miracle drug (3 articles)
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Fig. 3. Responsibility to address funding concerns.
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contrast, the small subset of CF patients eligible to receive
Kalydeco was described in 71 Canadian articles (48.6%, 71/146)
and in 91 U.S. articles (63.2%, 91/144). The term “orphan drug”
only appeared in 19 articles (6.6% 19/290) and only 13 articles
(4.5%, 13/290) defined the term, with no real difference in
coverage between the two countries.
We tracked adjectives and descriptors for Kalydeco in the
articles (Table 1). 126 Canadian news articles used adjectives and
other descriptors for Kalydeco (86.3%, 126/144), most often
within stories with a human interest frame (71%, 104/146). In the
U.S., only 28 articles (19.4%, 28/144) used adjectives and
descriptors for Kalydeco, which were primarily in articles with a
financial/economic frame (10 articles) or a medical/scientific
frame (11 articles).3.3. Financial and economic aspects of Kalydeco
Kalydeco appears to have prompted two main financial and/
or economic concerns: 1) the cost of drug development and the
CFF's involvement, and 2) the “consumer” cost of Kalydeco
and who should pay for this expensive treatment. The role of
the CFF in the development of Kalydeco was not a dominant
theme in news articles, but explanation of CFF's involvement
appeared mostly in U.S. articles (20.1%, 29/144), in compar-
ison to only 5 Canadian articles (3.4%, 5/146). For U.S. articles
discussing the issue, 4 were critical, 21 were supportive, and 44/146,
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Fig. 2. Attribution of cost of Kalydeco to different actors.were neutral about the subject. Only 1 Canadian article was
supportive and the rest remained neutral on the topic.
The cost of Kalydeco was frequently mentioned in Canadian
articles (81.5%, 119/146), compared to only 53 U.S. articles
(36.8%, 53/144), and referred to Kalydeco's high “consumer”
price and the cost of its development. We coded articles for
whether the cost of Kalydeco was mentioned in relation to the
“consumer” cost to patients, the government, or the healthcare
system, and whether the cost associated with its development
was mentioned in relation to Vertex or the CFF's investment
(Fig. 2).
Finally, responsibility for funding the cost of the treatment
was a dominant theme in Canadian newspapers (95.2%, 139/
146), whereas this issue appeared in only 27 of U.S. articles
(18.8%, 27/144). While responsibility for paying for Kalydeco
was distributed across a few different actors in U.S. articles,
most of the responsibility for paying for Kalydeco lay on the
government in Canadian articles. (Fig. 3).3.4. Benefits and harms of funding Kalydeco
Discussion of the benefits of funding Kalydeco was more
common than discussion of harms or concerns with funding.
Benefits were discussed in 113 Canadian articles (77.4%, 113/
146) and 35 U.S. articles (24.3%, 35/144). Canadian articles
focused primarily on the benefits to CF patients (Table 2),
while U.S. articles included discussion of benefits of using
charitable money for drug development (Table 3).Table 2
Benefits mentioned in Canadian articles.
Benefits of funding for patient access
Saves CF patients' lives 78/146 53.4%
Improves quality of life 7 4.8%
First treatment to address underlying causes of CF 4 2.7%
No specific benefits mentioned 2 1.4%
Drug reduces suffering and further treatments
(e.g., lung transplants)
24 16.4%
Good example of personalized medicine
(or Precision Medicine)
1 0.7%
Table 3
Benefits mentioned in US articles.
Benefits of funding for patient access
Saves CF patients' lives 10/144 6.9%
Improves quality of life 8 5.6%
First treatment to address underlying causes of CF 7 4.9%
Extend life expectancy 3 2.1%
Reduce financial burden on patients 2 1.4%
No specific benefits mentioned 1 0.7%
Price reductions are ethically responsible and
institutionally plausible
1 0.7%
Benefits of using charitable money for drug development
Good example of personalized medicine
(or Precision Medicine)
11 7.6%
CFF made money 4 2.8%
Kalydeco not a cure and/or further research
still needed
2 1.4%
627C. Rachul et al. / Journal of Cystic Fibrosis 15 (2016) 624–629In contrast, only 42 Canadian articles (28.8%, 42/146)
mentioned harms or concerns of funding Kalydeco, compared
to only 6 U.S. articles (4.2%, 6/144). The most common harm
mentioned in Canadian articles pertained to the government's
and healthcare system's budgetary limitations (7.5%, 11/146).
Other concerns pertained to funding provided to pharmaceuti-
cal companies to develop drugs like Kalydeco without cost
controls and increased costs in other areas like private health
insurance rates.
3.5. Tone of articles
Finally, the overall tone of articles was assessed for whether
the articles were neutral, supportive, or opposed to funding
Kalydeco. Canadian articles were, for the most part, supportive
of government funding for Kalydeco (86.3%, 126/146), with
111 (98.2%, 111/113) Canadian human interest articles
reflective of this position. In comparison, U.S. articles were
generally neutral regardless of the article's frame.
4. Discussion
While there are many similarities between the U.S. and Canada
in terms of Kalydeco's magnitude of price, patient eligibility, and
regulatory status as an approved drug, the news coverage of
Kalydeco tells very different stories in the two countries. These
differences may have developed as a result of their different
healthcare systems, and may also reflect subtle differences in the
news media industries between the two countries.
In Canada, Kalydeco is largely a story about increasing patient
access through full government funding for all patients. Kalydeco
is frequently described as a life-saving wonder drug, which is
further demonstrated by the frequent human interest framing of
news articles that highlight patient and caregiver stories about
how Kalydeco has changed their lives. This positive portrayal of
Kalydeco as a groundbreaking, life-saving medicine is reinforced
by the fact that less than half of Canadian articles mention the
rarity of the genetic variant and the very small patient population
that Kalydeco is effective to treat. With very little discussion of
the concerns associated with providing full funding, the Canadiannews coverage provides little room for discussions about whether
Kalydeco should or should not be publicly funded.
Indeed, Canadian newspaper coverage was overwhelmingly
supportive of government funding for Kalydeco. Despite the
fact that governments are facing mounting health care costs
with limited resources [9], only 7.5% of Canadian articles
mentioned any budgetary limitations in funding Kalydeco. The
lack of recognition of these financial constraints is echoed in
the vast majority of Canadian articles which held the
government responsible for funding concerns. The failure in
most articles to discuss Vertex's responsibility or role in setting
the price of Kalydeco illustrates a lack of engagement with the
issue of how the $300,000 per year price tag – mentioned in
more than 80% of Canadian articles – was arrived at. This
contrasts with discussions among the medical community that
have questioned the basis on which Vertex arrived at the price
[3].
Conversely, in U.S. articles, Kalydeco is largely an
economic story praising the innovative partnerships between
charitable organizations and pharmaceutical companies, and the
financial gain that Kalydeco and other orphan drugs bring to a
lagging biomedical industry. News coverage also highlights the
medical and scientific breakthrough for both the treatment of
CF and precision (or personalized) medicine. Although the role
of the CFF in Kalydeco's development was only discussed in
20% of U.S. articles, it is notable that 21 of these 29 articles
were supportive of this relationship with only 4 articles
predominantly critical. One particular criticism of this model
is that the investment in industry of money subject to charitable
tax advantages essentially creates a public subsidy for drug
development with little or no accountability [24]. Additional
concerns have been raised regarding “institutional corruption,
public trust, research agenda distortion, and disproportionate
funding to the size of the affected population” [24]. The CFF
has specifically been criticized for its failure to push back
against Vertex in setting the high price of Kalydeco, and the
enormous financial benefit it earned as a result of the price
Vertex is charging, while some patients, whose interests the
Foundation should be protecting, face access barriers to the
drug as a result of its price tag [24,25].
Irrespective of these concerns, the CFF's investment in
Kalydeco and $3.3 billion return has been an example to other
patient advocacy organizations, many of which are now
investing their own charitable dollars in research and drug
development [6,11,24]. These organizations may be able to
leverage the positive newspaper coverage of Kalydeco and
venture philanthropy as they engage with the private sector.
This will also be an interesting issue to follow as the CFF
continues to decide how to use its revenue from the sale of its
royalty rights. Notably, the Foundation appears to be prioritiz-
ing investment in further research and drug development over
financial assistance to patients who cannot afford the high cost
of Kalydeco [7].
There is very little discussion in the U.S. news coverage
about how patients will afford the medication or whether
someone else should foot the bill. This is likely because, unlike
in Canada, there was little debate or controversy about whether
628 C. Rachul et al. / Journal of Cystic Fibrosis 15 (2016) 624–629Medicaid or private insurers should reimburse Kalydeco, and as
a result, coverage for Kalydeco was provided to U.S. patients
much quicker than those in other jurisdictions [10]. However,
as Medicaid budgets are becoming increasingly strained by
high-cost specialty drugs [26], the absence of discussion in the
U.S. newspaper articles about the impact of Kalydeco on
Medicaid programs is notable.
In Canadian newspaper coverage, the failure to engagewith the
issue of budgetary limitations and to focus so strongly on patient
narratives may also be explained by differences in patient access
both within Canada and between Canada and other countries.
During the negotiation period between the Pan-Canadian Pricing
Alliance andVertex and the subsequent decision-making period in
which provinces contemplated funding the drug, patients in the
U.S. and several other countries [14], as well as patients in Canada
with private insurance plans covering Kalydeco [13], were already
receiving and benefiting from Kalydeco while those in need of
public assistance had to wait. The perceived inequity in access
may have driven the discussions to focus on the needs of patients
waiting for public funding of the drug. The quickness with which
Kalydeco was reimbursed in the U.S. may also have impacted the
newspaper coverage in Canada that seems to assume – with very
little discussion of potential harms or concerns – that Kalydeco
should be publicly funded.
The focus of Canadian coverage on patient stories is also
consistent with other studies that have found a similar tendency
of news coverage to focus on patient perspectives when
reporting on drug reimbursement [27,28]. Media coverage of
this nature may reflect the “rule of rescue” imperative in which
there is a perceived moral obligation to save or help identifiable
patients irrespective of cost or the resulting impact on available
healthcare resources [27,28]. In this regard, greater attention is
given to the needs of individual patients than the need for
evidence-based, sustainable reimbursement and allocation
decisions aimed at benefiting the population at large.
Although our findings are restricted to newspaper coverage
in Canada and the U.S., they may be of interest elsewhere,
particularly in jurisdictions where – similar to Canada – there
was greater reticence to publicly fund the drug [11,12]. Media
coverage in some of these jurisdictions, such as Australia and
the UK, which have their own models of universal healthcare,
appear to frame the story of Kalydeco similar to Canadian newsTable 4
Examples of headlines from news stories in other jurisdictions with universal
health coverage.
“Cystic Fibrosis win” (Shepparton News, October 28, 2014) — Australia
“Treatment offers hope to CF sufferers” (The Irish Times, June 26, 2014)— Ireland
“Victory in fight for drugs access” (Scottish Daily Record,
February 1, 2014)— Scotland
“Teen urges government to fund wonder medicines” (Barry and District News,
October 17, 2013)— Wales
“The price of life is unaffordable” (Herald-Sun, November 7, 2013)— Australia
“If Evie doesn't get this drug she'll die young… putting a cost on her life is
shocking” (Scottish Daily Record, January 16, 2013)— Scotland
“Our Caroline's been condemned to a slow and lingering death…; Helpless
parents' outrage as wonder drug denied for daughter battling deadly lung disease”
(Sunday Mercury, October 28, 2012)— Englandcoverage. Newspaper headlines from these regions indicate that
news coverage is often framed as human interest stories about
patients seeking government funding for Kalydeco (Table 4).
Future policy development for rare diseases and orphan
drugs may be influenced by discussions taking place in the
popular media [17]. The lack of nuanced discussion in
newspaper coverage in Canada and the U.S. regarding the
complexity of reimbursement decisions for high-cost, specialty
drugs may be of concern for policymakers within these
jurisdictions and abroad as drug prices continue to rise. The
experience with Kalydeco in the UK demonstrates that one
jurisdiction's decision to provide public funding could have a
ripple effect for other jurisdictions faced with the same decision
[12]. The discussion about Kalydeco within the U.S. and
Canada therefore has relevance beyond the borders of these two
countries and may be of interest to countries around the world
that are similarly struggling with funding decisions of this
nature and could be impacted by decisions to reimburse high
cost drugs in the U.S. and abroad.
The sustainability of a drug pricing system that results in
prices of this scale is in doubt, especially as the personalized
medicine movement continues where we can expect to see an
ever increasing number of treatments tailored to specific
genetic variations [1,10,29]. It will be particularly relevant to
follow the development of Vertex's new CF drug, Orkambi®
(lumacaftor/ivacaftor), which received FDA approval and is
aimed at a much larger segment of the CF patient population
[30]. As many jurisdictions have now provided public funding
for patients' Kalydeco treatments, pressure to similarly fund
Orkambi may be felt by healthcare systems around the world.
Reportedly priced at $259,000 per patient per year [7], the
resulting impact on healthcare systems can be expected to be
much greater, and it will be interesting to see if media coverage
starts to grapple with the policy issues involved in providing
coverage for this high-cost medication.Acknowledgments
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